Faeth Therapeutics
FTH
9 hedge funds and large institutions have $466K invested in Faeth Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
1.63% less ownership
Funds ownership: 5.54% → 3.91% (-1.6%)
10% less funds holding
Funds holding: 10 → 9 (-1)
22% less capital invested
Capital invested by funds: $600K → $466K (-$134K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$86.4K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$398 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$250K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$10.5K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
-$6.01K |
FTH Hedge Fund Activity: Q3 2025 in Review
9 of the 7,643 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q3 2025, worth a combined $466K — down 22% from $600K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of FTH and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $86.4K. The largest seller was Vanguard Group, exiting entirely with an estimated $250K sold.
- 9 institutional investors held Faeth Therapeutics (FTH) as of Q3 2025, down from 10 in Q2 2025.
- Funds reported $466K of Faeth Therapeutics stock for Q3 2025, down 22% quarter-over-quarter.
- 1 fund opened new Faeth Therapeutics positions in Q3 2025 and 2 closed out, a net change of -1 holder.
- The largest Faeth Therapeutics buyer in Q3 2025 was Renaissance Technologies, an estimated $86.4K added.
- The largest Faeth Therapeutics seller in Q3 2025 was Vanguard Group, an estimated $250K sold.
Based on aggregated 13F filings for Q3 2025.